Arcturus Therapeutics Holdings Inc Overview
Pro stress-test →Arcturus Therapeutics is a clinical-stage mRNA medicines company focused on rare diseases including cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus infectious disease vaccines. The company utilizes its proprietary LUNAR® lipid nanoparticle technology platform to deliver mRNA therapeutics and has demonstrated promising Phase 2 interim data in both CF and OTC programs.
Strategic Profile
Pro stress-test →Arcturus differentiates through its LUNAR delivery platform designed for tissue-specific mRNA targeting, enabling treatment of genetic disorders where conventional therapies are limited. The company is advancing multiple pipeline candidates toward pivotal studies, with regulatory alignment meetings planned for early 2026 and commercial partnerships including CSL for vaccine commercialization.
Competitive Landscape
Pro stress-test →Arcturus competes in the rare disease mRNA therapeutics space against companies like Moderna, Intellia Therapeutics, Sarepta Therapeutics, Sangamo Therapeutics, and BioCryst Pharmaceuticals. The company's competitive advantage centers on its LUNAR lipid nanoparticle technology designed for liver and respiratory tissue targeting, though it faces competition from larger, better-capitalized biotech firms.
Industry Context
Arcturus Therapeutics Holdings Inc operates in Biotechnology - mRNA Therapeutics & Rare Genetic Diseases.
Key facts
Founded: 2013 · Headquarters: San Diego, California · Revenue: $110M · Market cap: $323M